Jamieson is pleased to announce it has advised Tim Clover (CEO), Darren Millington (CFO) and the management team of Rayner, the global ophthalmology business, on the sale of the company to CVC Capital Partners from Phoenix Equity Partners.
Rayner manufactures and develops intraocular lenses (IOLs) and is a global leader in ophthalmic innovation, helping to deliver surgeons and patients with high quality visual outcomes. Based in their global headquarters in Worthing, Rayner is the only manufacturer of IOLs in the UK, having manufactured the world’s first IOL in 1949. Today, Rayner sells to over 80 countries and helps improve eyesight for over 300,000 patients per year.
“Jamieson came with a strong recommendation and we were very grateful for their support during our transaction. Their guidance was always clear, wise and quick. It helped us conclude a better incentive scheme for management but aligned to our investment partner.”
Tim Clover, CEO
Stuart Coventry, David Kirkpatrick, Henry Balcerak and Tom Darley advised the management team on their reinvestment and the terms of the new management incentive with CVC.
